KRAKOW, Poland, Sept. 3,
2019 /PRNewswire/ -- Selvita (WSE: SLV) today announced that
Pawel Przewiezlikowski, Chief Executive Officer, will present at
the following conferences in New
York:
Event: H.C. Wainwright 21st Annual Global Investment Conference,
Sept. 8-10, 2019
Location: Lotte New York Palace Hotel
Date/Time: Monday, Sept. 9, at 5:30
p.m. EDT
Webcast: A live and archived webcast of this presentation will also
be made available at http://wsw.com/webcast/hcw5/selv/.
Event: Rambam Foundation Life Sciences Symposium, Sept. 10, 2019
Location: The YJP Mansion
Date/Time: Tuesday, Sept. 10, at
9:15 a.m. EDT
About Selvita
Selvita is developing novel small molecule therapies that
address emerging targets and novel pathways in oncology with
industry-leading research expertise. Pipeline candidates make use
of diverse therapeutic mechanisms driven by emerging knowledge of
cancer biology, including small molecules directed at kinase,
synthetic lethality, immuno-oncology and cancer metabolism targets.
SEL120 is a selective CDK8 kinase inhibitor in Phase 1 clinical
development for the treatment of acute myeloid leukemia and
myelodysplastic syndromes, with potential for development in
multiple hematological cancers and solid tumor indications.
SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the
Menarini Group in Phase 1/2 clinical development for the treatment
of acute myeloid leukemia. Selvita is headquartered in Krakow, Poland, with offices in the U.S. and U.K.
Ardigen, a provider of precision medicine and artificial
intelligence services, and NodThera, a company developing a new
class of medicines to treat chronic inflammation, were launched by
Selvita. In March 2019, Selvita
announced the intent to split its oncology development and research
services divisions into separate companies.
View original
content:http://www.prnewswire.com/news-releases/selvita-to-present-at-upcoming-conferences-in-september-300910328.html
SOURCE Selvita